NMDA receptor subunits: function and pharmacology.

N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels widely expressed in the central nervous system that play key roles in excitatory synaptic transmission. Because of their involvement in numerous neurological disorders, NMDARs are also targets of therapeutic interest. NMDARs occur as multiple subtypes which differ in their subunit composition and in their biophysical and pharmacological properties. In particular, NMDARs contain a diversity of sites at which endogenous ligands or pharmacological agents can act to modulate receptor activity in a subunit-selective manner, and recent structural and functional data have started to reveal the molecular determinants for this subunit selectivity. These include the binding sites for glutamate, the ion-channel pore and the recently identified allosteric sites on the N-terminal domain. Other potential sites yet unexplored by medicinal chemistry programs are also considered, in particular at the interface between subunits. Given the growing body of evidence that diverse brain disorders implicate different NMDAR subtypes, such as NR2B in pain or NR3A in white matter injury, there is a growing interest in exploiting the pharmacological heterogeneity of NMDARs for the development of novel NMDAR subtype-selective compounds.

[1]  P. Paoletti,et al.  Modulation of Triheteromeric NMDA Receptors by N-Terminal Domain Ligands , 2005, Neuron.

[2]  S. Cull-Candy,et al.  Role of Distinct NMDA Receptor Subtypes at Central Synapses , 2004, Science's STKE.

[3]  P. Headley,et al.  NMDA antagonists and neuropathic pain--multiple drug targets and multiple uses. , 2005, Current pharmaceutical design.

[4]  Karin E. Borgmann-Winter,et al.  Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.

[5]  T. Yamakura,et al.  Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. , 1993, Neuroreport.

[6]  K. Williams,et al.  Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. , 2002, Molecular pharmacology.

[7]  F. Menniti,et al.  Molecular Mechanism of AMPA Receptor Noncompetitive Antagonism , 2005, Neuron.

[8]  Orally efficacious NR2B-selective NMDA receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.

[9]  M. Salter,et al.  NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury , 2005, Nature.

[10]  F. Menniti,et al.  Antagonists selective for NMDA receptors containing the NR2B subunit. , 1999, Current pharmaceutical design.

[11]  Marc G Caron,et al.  Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia , 1999, Cell.

[12]  J. Kemp,et al.  Identification of Critical Residues in the Amino Terminal Domain of the Human NR2B Subunit Involved in the RO 25-6981 Binding Pocket , 2003, Journal of Pharmacology and Experimental Therapeutics.

[13]  R. Thompson,et al.  Importance of zinc in the central nervous system: the zinc-containing neuron. , 2000, The Journal of nutrition.

[14]  S. Traynelis,et al.  Control of Voltage-independent Zinc Inhibition of Nmda Receptors by the Nr1 Subunit , 2022 .

[15]  R. North,et al.  NMDA Receptors Mediate Neuron-to-Glia Signaling in Mouse Cortical Astrocytes , 2006, The Journal of Neuroscience.

[16]  D. Jane,et al.  The effect of competitive antagonist chain length on NMDA receptor subunit selectivity , 2005, Neuropharmacology.

[17]  H. Tse,et al.  Structure–activity analysis of a novel NR2C/NR2D‐preferring NMDA receptor antagonist: 1‐(phenanthrene‐2‐carbonyl) piperazine‐2,3‐dicarboxylic acid , 2004, British journal of pharmacology.

[18]  K. Williams,et al.  A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein. , 1999, Molecular pharmacology.

[19]  J. Kemp,et al.  Severe Impairment of NMDA Receptor Function in Mice Carrying Targeted Point Mutations in the Glycine Binding Site Results in Drug-Resistant Nonhabituating Hyperactivity , 2002, The Journal of Neuroscience.

[20]  J. Kemp,et al.  Ionotropic and metabotropic glutamate receptor structure and pharmacology , 2005, Psychopharmacology.

[21]  T. Kuner,et al.  Subunit‐specific block of cloned NMDA receptors by argiotoxin636 , 1993, FEBS letters.

[22]  K Williams,et al.  Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. , 1993, Molecular pharmacology.

[23]  P. Ascher,et al.  High-Affinity Zinc Inhibition of NMDA NR1–NR2A Receptors , 1997, The Journal of Neuroscience.

[24]  L. Wollmuth,et al.  Structure and gating of the glutamate receptor ion channel , 2004, Trends in Neurosciences.

[25]  J. Kemp,et al.  NMDA receptor pathways as drug targets , 2002, Nature Neuroscience.

[26]  A. Fayyazuddin,et al.  Molecular Organization of a Zinc Binding N-Terminal Modulatory Domain in a NMDA Receptor Subunit , 2000, Neuron.

[27]  M. Mayer.  Glutamate receptors at atomic resolution , 2006, Nature.

[28]  T. Kuner,et al.  Multiple Structural Elements Determine Subunit Specificity of Mg2+ Block in NMDA Receptor Channels , 1996, The Journal of Neuroscience.

[29]  S. Lechner.  Glutamate-based therapeutic approaches: inhibitors of glycine transport. , 2006, Current opinion in pharmacology.

[30]  G. Collingridge,et al.  Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells , 1996, British journal of pharmacology.

[31]  M. Mayer,et al.  Crystal Structures of the Kainate Receptor GluR5 Ligand Binding Core Dimer with Novel GluR5-Selective Antagonists , 2006, The Journal of Neuroscience.

[32]  Chin-Chun Lu,et al.  Functional Characterization of Human N‐Methyl‐d‐Aspartate Subtype 1A/2D Receptors , 1998, Journal of neurochemistry.

[33]  D. Attwell,et al.  NMDA receptors are expressed in oligodendrocytes and activated in ischaemia , 2005, Nature.

[34]  P. Paoletti,et al.  Relating NMDA Receptor Function to Receptor Subunit Composition: Limitations of the Pharmacological Approach , 2006, The Journal of Neuroscience.

[35]  S. Schorge,et al.  Studies of NMDA Receptor Function and Stoichiometry with Truncated and Tandem Subunits , 2003, The Journal of Neuroscience.

[36]  B. Trapp,et al.  NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia , 2006, Nature.

[37]  D. Skifter,et al.  Identification of Subunit- and Antagonist-Specific Amino Acid Residues in the N-Methyl-d-aspartate Receptor Glutamate-Binding Pocket , 2005, Journal of Pharmacology and Experimental Therapeutics.

[38]  Bita Moghaddam,et al.  Bringing Order to the Glutamate Chaos in Schizophrenia , 2003, Neuron.

[39]  NMDA Receptor Subunits: Function and Pharmacology , 2007 .

[40]  J. Coyle,et al.  Glutamatergic mechanisms in schizophrenia. , 2003, Annual review of pharmacology and toxicology.

[41]  P. Paoletti,et al.  Mapping the Binding Site of the Neuroprotectant Ifenprodil on NMDA Receptors , 2002, The Journal of Neuroscience.

[42]  J. Kemp,et al.  A novel mechanism of activity‐dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. , 1996, The Journal of physiology.

[43]  Eric Gouaux,et al.  Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand‐binding core , 2003, The EMBO journal.

[44]  J. Kemp,et al.  Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. , 1997, The Journal of pharmacology and experimental therapeutics.

[45]  H. Monyer,et al.  Differentiation of glycine antagonist sites of N-methyl-D-aspartate receptor subtypes. Preferential interaction of CGP 61594 with NR1/2B receptors. , 1998, The Journal of biological chemistry.

[46]  M. Sheng,et al.  Role of NMDA Receptor Subtypes in Governing the Direction of Hippocampal Synaptic Plasticity , 2004, Science.

[47]  K. Williams,et al.  N1-dansyl-spermine and N1-(n-octanesulfonyl)-spermine, novel glutamate receptor antagonists: block and permeation of N-methyl-D-aspartate receptors. , 1997, Molecular pharmacology.

[48]  M. Mayer,et al.  Characterization of a Soluble Ligand Binding Domain of the NMDA Receptor Regulatory Subunit NR3A , 2006, The Journal of Neuroscience.

[49]  K. Wafford,et al.  Identification of Molecular Determinants That Are Important in the Assembly of N-Methyl-d-aspartate Receptors* , 2001, The Journal of Biological Chemistry.

[50]  T. Yamakura,et al.  Subunit- and site-specific pharmacology of the NMDA receptor channel , 1999, Progress in Neurobiology.

[51]  E. Gouaux,et al.  Structure of a glutamate-receptor ligand-binding core in complex with kainate , 1998, Nature.

[52]  M. Kelly,et al.  Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists. , 2006, Current topics in medicinal chemistry.

[53]  P. Paoletti,et al.  The Micromolar Zinc-Binding Domain on the NMDA Receptor Subunit NR2B , 2005, The Journal of Neuroscience.

[54]  Eric Gouaux,et al.  Mechanism of Partial Agonist Action at the NR1 Subunit of NMDA Receptors , 2005, Neuron.

[55]  M. Mayer,et al.  Mechanism of glutamate receptor desensitization , 2002, Nature.

[56]  E. Gouaux,et al.  Subunit arrangement and function in NMDA receptors , 2005, Nature.

[57]  Joshua T Dudman,et al.  Mechanism of Positive Allosteric Modulators Acting on AMPA Receptors , 2005, The Journal of Neuroscience.

[58]  S. Lipton,et al.  Identification and Mechanism of Action of Two Histidine Residues Underlying High-Affinity Zn2+ Inhibition of the NMDA Receptor , 1999, Neuron.

[59]  Jiankun Cui,et al.  Characterization and comparison of the NR3A subunit of the NMDA receptor in recombinant systems and primary cortical neurons. , 2002, Journal of neurophysiology.

[60]  R. Dingledine,et al.  The glutamate receptor ion channels. , 1999, Pharmacological reviews.

[61]  R. Dingledine,et al.  Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition , 1998, Nature Neuroscience.

[62]  M. Yuzaki,et al.  Cloning and characterization of a novel NMDA receptor subunit NR3B: a dominant subunit that reduces calcium permeability. , 2002, Brain research. Molecular brain research.